Liposome-encapsulated amphotericin B: a promising new treatment for disseminated fungal infections.

V. J. Wiebe, M. W. DeGregorio

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Amphotericin B therapy is hampered by numerous adverse effects but remains the treatment of choice for disseminated fungal infections. A new form of amphotericin B delivery, which utilizes liposome vesicles, is currently under investigation. Preliminary evidence suggests that liposome-encapsulated amphotericin B has a wider therapeutic index than free amphotericin B and allows for the use of larger total doses. The mechanism of reduced toxicity and enhanced activity may be associated with a liposome donor effect, an erythrocyte protective effect, and a liposome-targeting ability. Liposome-encapsulated amphotericin B tends to be entrapped or taken up by organs rich in reticuloendothelial cells--a particular advantage since disseminated fungal infections localize in these areas. This liposome-encapsulated preparation appears to represent a promising new form of antifungal therapy that may reduce the dose-limiting toxicities of amphotericin B and improve treatment response.

Original languageEnglish (US)
Pages (from-to)1097-1101
Number of pages5
JournalReviews of Infectious Diseases
Volume10
Issue number6
StatePublished - Nov 1988
Externally publishedYes

Fingerprint

Mycoses
Amphotericin B
Liposomes
Therapeutics
Erythrocytes

ASJC Scopus subject areas

  • Microbiology (medical)

Cite this

Liposome-encapsulated amphotericin B : a promising new treatment for disseminated fungal infections. / Wiebe, V. J.; DeGregorio, M. W.

In: Reviews of Infectious Diseases, Vol. 10, No. 6, 11.1988, p. 1097-1101.

Research output: Contribution to journalArticle

@article{daff2ffdc9874fb3862a27140763923a,
title = "Liposome-encapsulated amphotericin B: a promising new treatment for disseminated fungal infections.",
abstract = "Amphotericin B therapy is hampered by numerous adverse effects but remains the treatment of choice for disseminated fungal infections. A new form of amphotericin B delivery, which utilizes liposome vesicles, is currently under investigation. Preliminary evidence suggests that liposome-encapsulated amphotericin B has a wider therapeutic index than free amphotericin B and allows for the use of larger total doses. The mechanism of reduced toxicity and enhanced activity may be associated with a liposome donor effect, an erythrocyte protective effect, and a liposome-targeting ability. Liposome-encapsulated amphotericin B tends to be entrapped or taken up by organs rich in reticuloendothelial cells--a particular advantage since disseminated fungal infections localize in these areas. This liposome-encapsulated preparation appears to represent a promising new form of antifungal therapy that may reduce the dose-limiting toxicities of amphotericin B and improve treatment response.",
author = "Wiebe, {V. J.} and DeGregorio, {M. W.}",
year = "1988",
month = "11",
language = "English (US)",
volume = "10",
pages = "1097--1101",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "6",

}

TY - JOUR

T1 - Liposome-encapsulated amphotericin B

T2 - a promising new treatment for disseminated fungal infections.

AU - Wiebe, V. J.

AU - DeGregorio, M. W.

PY - 1988/11

Y1 - 1988/11

N2 - Amphotericin B therapy is hampered by numerous adverse effects but remains the treatment of choice for disseminated fungal infections. A new form of amphotericin B delivery, which utilizes liposome vesicles, is currently under investigation. Preliminary evidence suggests that liposome-encapsulated amphotericin B has a wider therapeutic index than free amphotericin B and allows for the use of larger total doses. The mechanism of reduced toxicity and enhanced activity may be associated with a liposome donor effect, an erythrocyte protective effect, and a liposome-targeting ability. Liposome-encapsulated amphotericin B tends to be entrapped or taken up by organs rich in reticuloendothelial cells--a particular advantage since disseminated fungal infections localize in these areas. This liposome-encapsulated preparation appears to represent a promising new form of antifungal therapy that may reduce the dose-limiting toxicities of amphotericin B and improve treatment response.

AB - Amphotericin B therapy is hampered by numerous adverse effects but remains the treatment of choice for disseminated fungal infections. A new form of amphotericin B delivery, which utilizes liposome vesicles, is currently under investigation. Preliminary evidence suggests that liposome-encapsulated amphotericin B has a wider therapeutic index than free amphotericin B and allows for the use of larger total doses. The mechanism of reduced toxicity and enhanced activity may be associated with a liposome donor effect, an erythrocyte protective effect, and a liposome-targeting ability. Liposome-encapsulated amphotericin B tends to be entrapped or taken up by organs rich in reticuloendothelial cells--a particular advantage since disseminated fungal infections localize in these areas. This liposome-encapsulated preparation appears to represent a promising new form of antifungal therapy that may reduce the dose-limiting toxicities of amphotericin B and improve treatment response.

UR - http://www.scopus.com/inward/record.url?scp=0024119161&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024119161&partnerID=8YFLogxK

M3 - Article

C2 - 3060940

AN - SCOPUS:0024119161

VL - 10

SP - 1097

EP - 1101

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 6

ER -